Vmbook Online ordering

Icons

The company you're referring to is ProPhase Labs, Inc. (PIP), a biotechnology company that is traded on the NASDAQ stock exchange. ProPhase Labs is focused on the research, development, and marketing of over-the-counter (OTC) drug products.

Here are some key points about ProPhase Labs:

1. Earnings: For the fiscal year 2020, ProPhase Labs reported net sales of $8.8 million, compared to $13.2 million in the previous year. The company's net loss for the year was $1.3 million, or $0.07 per share, compared to a net income of $3.8 million, or $0.21 per share, in the previous year.

2. Growth: ProPhase Labs has a history of developing and commercializing new products, such as its Cold-EEZE® brand of lozenges. However, the company's growth has been inconsistent in recent years, with fluctuations in sales and earnings.

3. Market Opportunity: The market for OTC drug products is large and growing, with opportunities for ProPhase Labs to expand its product line and increase its market share. The company's focus on the research, development, and marketing of OTC drug products positions it well to take advantage of this market opportunity.

4. Financial Position: ProPhase Labs had cash and cash equivalents of approximately $1.2 million as of December 31, 2020. The company's current liabilities exceeded its current assets as of that date, indicating a potential liquidity issue.

5. Risks: ProPhase Labs operates in a highly competitive industry, and the success of its products depends on various factors, including consumer preferences, competition, and regulatory approvals. Additionally, the company's financial position may limit its ability to invest in research and development, marketing, and other growth initiatives.

It's important to note that this information is subject to change and should be verified by consulting the company's financial statements and other public filings. As with any investment, it's recommended to consult with a financial advisor before making any investment decisions.